Courts around the country are circulating warnings about virus-bearing emails that purport to be notices of court hearings. Scott Christie, a former assistant U.S. attorney who headed the District of New Jersey office's Computer Hacking and Intellectual Property Section(and currently partner at Continue Reading
New Leadership, but the Same Mission, For Holiday Fund
As the 2013 Greater Newark Holiday Fund nears its end, the agency has announced changes in its leadership. However, Frank Ferruggia a partner at McCarter & English will continue to serve as a board member of the holiday fund. He has been elected Chairman of the Newark Regional Business Continue Reading
The Future of Real Estate? Our Dynamic Dozen Gets a Say
Martin Dowd, office leasing and urban redevelopment attorney at McCarter & English (Newark) was quoted in the article, "Because incentives under the Economic Opportunity Act lower the effective cost of occupancy of office space, I foresee some absorption by new business coming to the state, Continue Reading
Federal Circuit ruling another win for biotech industry
The U.S. Court of Appeals for the Federal Circuit has reinstated its ruling that a company’s isolation of human genetic material, and its process for using that material to determine the effectiveness of certain cancer therapies, meet the threshold test for patent-eligibility. McCarter & Continue Reading
The US Approach to Biosimilars Explained
5 Ways to Ramp Up Your Patent Portfolio
Off the Beaten Path
Zacharakis’s story When Maria Laccotripe Zacharakis started her molecular biology PhD at Boston University School of Medicine, she never envisioned herself as a lawyer. But partway through her research on the structure-function relationship of one of the proteins in “good” cholesterol, she Continue Reading
Biotechs, Pharma Look at What’s Next for Biosimilars
The rubber has hit the road in the debate over legislation, approved in March, to create a regulatory pathway for generic versions of cell-based drugs known as biosimilars. The U.S. Food and Drug Administration has yet to issue rules on the new law, which would give the “innovator companies” — those Continue Reading
Biotech industry focuses on how gene patent case turns out
The local biotechnology industry is on tenterhooks, waiting to see if a court ruling that invalidates patents on genes will be overturned. The federal court case, decided March 29, received an inordinate amount of attention from both the media and the legal community, prompting nine amicus briefs on Continue Reading